Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation
Rubén Martínez-Barricarte, … , Claire L. Harris, Santiago Rodríguez de Córdoba
Rubén Martínez-Barricarte, … , Claire L. Harris, Santiago Rodríguez de Córdoba
Published September 13, 2010
Citation Information: J Clin Invest. 2010;120(10):3702-3712. https://doi.org/10.1172/JCI43343.
View: Text | PDF
Research Article Nephrology

Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation

  • Text
  • PDF
Abstract

Dense deposit disease (DDD) is a severe renal disease characterized by accumulation of electron-dense material in the mesangium and glomerular basement membrane. Previously, DDD has been associated with deficiency of factor H (fH), a plasma regulator of the alternative pathway (AP) of complement activation, and studies in animal models have linked pathogenesis to the massive complement factor 3 (C3) activation caused by this deficiency. Here, we identified a unique DDD pedigree that associates disease with a mutation in the C3 gene. Mutant C3923ΔDG, which lacks 2 amino acids, could not be cleaved to C3b by the AP C3-convertase and was therefore the predominant circulating C3 protein in the patients. However, upon activation to C3b by proteases, or to C3(H2O) by spontaneous thioester hydrolysis, C3923ΔDG generated an active AP C3-convertase that was regulated normally by decay accelerating factor (DAF) but was resistant to decay by fH. Moreover, activated C3b923ΔDG and C3(H2O)923ΔDG were resistant to proteolysis by factor I (fI) in the presence of fH, but were efficiently inactivated in the presence of membrane cofactor protein (MCP). These characteristics cause a fluid phase–restricted AP dysregulation in the patients that continuously activated and consumed C3 produced by the normal C3 allele. These findings expose structural requirements in C3 that are critical for recognition of the substrate C3 by the AP C3-convertase and for the regulatory activities of fH, DAF, and MCP, all of which have implications for therapeutic developments.

Authors

Rubén Martínez-Barricarte, Meike Heurich, Francisco Valdes-Cañedo, Eduardo Vazquez-Martul, Eva Torreira, Tamara Montes, Agustín Tortajada, Sheila Pinto, Margarita Lopez-Trascasa, B. Paul Morgan, Oscar Llorca, Claire L. Harris, Santiago Rodríguez de Córdoba

×

Figure 7

Reduced affinity of fH for hydrolyzed C3923ΔDG impairs both decay of the mutant C3-convertase and fI-mediated inactivation of hydrolyzed C3923ΔDG.

Options: View larger image (or click on image) Download as PowerPoint
Reduced affinity of fH for hydrolyzed C3923ΔDG impairs both decay of the...
(A) Hydrolyzed C3WT (1,224 RU) or C3923ΔDG (1,067 RU) were thiol-coupled to a CM5 Biacore chip. The affinity for native fH was analyzed by flowing fH (1 μM to 8 nM) over the surface and determined by steady-state analysis. The affinity of fH for C3(H2O)923ΔDG was reduced 2-fold compared with C3WT. Values are mean ± SD of 3 determinations. (B) Convertase was formed on each hydrolyzed C3 surface by flowing fB and fD. After a period of natural decay, fH (0.9 μM) was injected for 60 seconds. Convertase formed by C3(H2O)WT (gray line) was efficiently decayed by fH, whereas the C3(H2O)923ΔDG convertase (black line) was inefficiently decayed. Binding (RU) of fH to the surface in the absence of the convertase was subtracted; curves illustrate decay of Bb. (C) In contrast, mutant convertase was efficiently decayed by DAF (0.4 μM). (D) Hydrolyzed C3WT or C3923ΔDG was thiol-coupled to a CM5 Biacore chip. Initial formation of convertase on each surface was assessed by flowing fB and fD (black line). After complete decay of the convertase, fH (0.33 μM) and fI (0.11 μM) were flowed across the surface for 5 minutes at 5 μl/min. Convertase was then formed again (gray lines) using identical conditions. Enzyme formation by C3(H2O)WT convertase was reduced 50% by fI/fH treatment, whereas enzyme formation from C3(H2O)923ΔDG convertase was hardly affected.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts